Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's Disease

Details for Australian Patent Application No. 2004240707 (hide)

Owner Nymox Pharmaceutical Corporation

Inventors Averback, Paul A.

Agent Baldwins

Pub. Number AU-A-2004240707

PCT Pub. Number WO2004/104029

Priority 10/444,070 23.05.03 US

Filing date 25 May 2004

Wipo publication date 2 December 2004

International Classifications

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 7/08 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

Event Publications

15 December 2005 PCT application entered the National Phase

  PCT publication WO2004/104029 Priority application(s): WO2004/104029

24 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004240716-Method for synthesising heterocyclic compounds from thiourea derivatives

2004240705-Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists